- Home
- ANIX vs OPTN Comparison
ANIX vs OPTN Comparison
Compare ANIX & OPTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANIX
- OPTN
- Stock Information
- Founded
- ANIX 1982
- OPTN 2010
- Country
- ANIX United States
- OPTN United States
- Employees
- ANIX N/A
- OPTN N/A
- Industry
- ANIX Biotechnology: Pharmaceutical Preparations
- OPTN Biotechnology: Pharmaceutical Preparations
- Sector
- ANIX Health Care
- OPTN Health Care
- Exchange
- ANIX Nasdaq
- OPTN Nasdaq
- Market Cap
- ANIX 101.4M
- OPTN 99.7M
- IPO Year
- ANIX 1987
- OPTN 2017
- Fundamental
- Price
- ANIX $3.08
- OPTN $0.44
- Analyst Decision
- ANIX Strong Buy
- OPTN Strong Buy
- Analyst Count
- ANIX 2
- OPTN 3
- Target Price
- ANIX $8.50
- OPTN $3.00
- AVG Volume (30 Days)
- ANIX 128.3K
- OPTN 658.7K
- Earning Date
- ANIX 01-14-2025
- OPTN 11-12-2024
- Dividend Yield
- ANIX N/A
- OPTN N/A
- EPS Growth
- ANIX N/A
- OPTN N/A
- EPS
- ANIX N/A
- OPTN N/A
- Revenue
- ANIX N/A
- OPTN $75,672,000.00
- Revenue This Year
- ANIX N/A
- OPTN $24.44
- Revenue Next Year
- ANIX N/A
- OPTN $49.00
- P/E Ratio
- ANIX N/A
- OPTN N/A
- Revenue Growth
- ANIX N/A
- OPTN 5.13
- 52 Week Low
- ANIX $2.15
- OPTN $0.41
- 52 Week High
- ANIX $5.13
- OPTN $2.10
- Technical
- Relative Strength Index (RSI)
- ANIX 42.34
- OPTN 24.21
- Support Level
- ANIX $3.07
- OPTN $0.66
- Resistance Level
- ANIX $4.20
- OPTN $0.81
- Average True Range (ATR)
- ANIX 0.30
- OPTN 0.06
- MACD
- ANIX -0.06
- OPTN -0.03
- Stochastic Oscillator
- ANIX 2.61
- OPTN 5.68
About ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About OPTN OptiNose Inc.
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.